drugset / Trial / NCT05310643
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
NaSingle-groupOpen-labelTreatment
Summary
NIPIRESCUE evaluates nivolumab and ipilimumab in patients with MSI/dMMR mCRC resistant to anti-PD1 monotherapy and previously treated with fluoropyrimidine, oxaliplatine, irinotecan, and anti- vascular endothelial growth factor (VEGF) or anti- epidermal growth factor receptor (EGFR) therapy.
Timeline
- Start
- 2022-05-05
- Primary completion
- 2025-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |